Avapritinib
NAVIGATOR
Blueprint Medicines · Phase 1 · Completed · Enrollment 250
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Avapritinib 300 or 400 mg, PDGFRA exon 18 | unresectable or metastatic GIST with PDGFRA exon 18 mutation (n = 43) | 300 or 400 mg | Single arm | n/r | overall response rate (independent review): 84%, median follow up 10.6 months |
| Avapritinib, PDGFRA D842V subgroup | PDGFRA D842V (n = 38) | 300 or 400 mg | Single arm | n/r | overall response rate (independent review): 89%, median follow up 10.6 months |
| Avapritinib, all GIST safety population | GIST, 267 patients in intracranial hemorrhage pooled count | 300 or 400 mg | Single arm | n/r | n/r |